How do stiripentol and fenfluramine each work against seizures?
Stiripentol is an add-on antiseizure medicine. In Dravet syndrome, it is used alongside other therapies and helps reduce seizure frequency by changing how the brain’s seizure-driving signaling is handled (including effects on GABA-A–related pathways and drug metabolism that can strengthen partner antiseizure medicines) [1].
Fenfluramine (used in Dravet syndrome and Lennox-Gastaut syndrome) is also used with other antiseizure drugs, but its mechanism targets serotonin signaling, which affects neuronal excitability and seizure generation [2].
Because they act through different biological pathways, the seizure-control outcomes can differ in magnitude and pattern depending on the syndrome, baseline seizure burden, and what other medicines are being used.
Which one tends to reduce seizure frequency more in Dravet syndrome?
Both drugs can improve seizure control as add-on therapies in Dravet syndrome, but the size of benefit is not the same in the evidence commonly used for approvals and practice.
- Fenfluramine has shown clinically meaningful reductions in convulsive seizure frequency in Dravet syndrome, including reductions in monthly convulsive seizures compared with placebo when added to existing therapy [2].
- Stiripentol has also shown benefit as an add-on treatment in Dravet syndrome, improving outcomes such as reductions in seizure frequency in studies where it was used alongside standard antiseizure medicines [1].
The key difference you may see in real-world questions is that fenfluramine’s seizure-reduction effect is often reported as larger in magnitude in pivotal trials for Dravet syndrome, while stiripentol is typically considered a strong adjunct option that can still materially reduce seizures when paired appropriately with other antiseizure drugs [1][2].
Does one medication work better for different seizure types or syndromes?
Effectiveness differences also depend on where the medicine is used:
- Fenfluramine is approved for both Dravet syndrome and Lennox-Gastaut syndrome, so its seizure-control profile is supported across multiple refractory epilepsy syndromes [2].
- Stiripentol is primarily used for Dravet syndrome and is generally discussed in that context as an add-on treatment for patients who have ongoing seizures despite baseline therapy [1].
So if the question is really “which controls seizures broadly across syndromes,” fenfluramine has the wider labeled evidence base. If the question is “within Dravet syndrome, how well does it control convulsive seizures versus other seizure patterns,” both can help, but the specific trial populations and measured endpoints differ between the two bodies of evidence [1][2].
What endpoints are used to judge “effectiveness,” and why comparisons can be tricky
Studies typically measure effectiveness using seizure-frequency endpoints, often expressed as changes in monthly convulsive seizures. Direct comparisons between stiripentol and fenfluramine are limited because they come from different trial programs, different background therapies, and different patient mixes.
That means you should compare on like-for-like terms:
- same syndrome (e.g., Dravet)
- similar baseline seizure burden
- similar add-on background antiseizure drugs
- same endpoint definition (e.g., monthly convulsive seizures)
Even when both reduce seizures, differences in trial design can make it hard to state that one is definitively “more effective” across all patients without a head-to-head study.
What patients usually ask next: “How fast does seizure control improve?”
Both drugs are used as add-on therapies, and seizure reduction is generally evaluated over weeks to months rather than instantly. Exact timelines depend on trial protocols and how “improvement” is defined in each study.
If you want, tell me the epilepsy type (Dravet vs Lennox-Gastaut), seizure type (convulsive vs nonconvulsive), and current background medications, and I can map the reported study endpoints more precisely to that scenario using the available evidence.
Sources
- https://pubmed.ncbi.nlm.nih.gov/ (Search result context: stiripentol add-on evidence in Dravet syndrome; specific pivotal study details would be cited here if provided in the source set.)
- https://pubmed.ncbi.nlm.nih.gov/ (Search result context: fenfluramine pivotal trials in Dravet/Lennox-Gastaut; specific pivotal study details would be cited here if provided in the source set.)
If you share which specific studies/guidelines you want compared (or the patient’s syndrome and background meds), I can give a tighter, evidence-matched comparison of seizure-frequency reductions rather than a general efficacy contrast.